US2012277172A1PendingUtilityA1
Carbohydrate-lipid constructs and their use in preventing or treating viral infection
Est. expiryApr 27, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Stephen Henry
A61K 31/7028A61P 31/12A61K 31/702A61K 31/685A61K 31/70A61K 35/18A61P 31/18
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.
Claims
exact text as granted — not AI-modified1 - 72 . (canceled)
73 . An antiviral preparation comprising pharmaceutically acceptable formulants and a construct of the formula F-S 1 -S 2 -L where: F is selected from the group consisting of glycotopes of ligands for one or more receptors expressed by a virus; S 1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl or 5-aminopentyl; S 2 is —CO(CH 2 ) 3 CO—, —CO(CH 2 ) 4 CO— or —CO(CH 2 ) 5 CO—; and L is phosphatidylethanolamine.
74 . The preparation of claim 73 where L is 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine.
75 . The preparation of claim 73 where the preparation is formulated for administration by intravascular injection.
76 . The preparation of claim 75 where the preparation is formulated for administration by intravenous injection.
77 . The preparation of claim 73 where the preparation is in the form of a cream or suppository.
78 . The preparation of claim 73 where the glycoside is 1-O—(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl (Gb3), n is 4 and p is 3.
79 . The preparation of claim 78 where the construct has the structure:
where M is a monovalent cation.
80 . The preparation of claim 78 where the construct has the structure:
where M is a monovalent cation.
81 . The preparation of claim 78 where the construct has the structure:
where M is a monovalent cation.
82 . The preparation of claim 78 where the construct has the structure:
where M is a monovalent cation.
83 . The preparation of claim 78 where the virus is the human immunodeficiency virus (HIV).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.